Date Filed | Type | Description |
10/04/2023 |
8-K
| Investor presentation |
10/03/2023 |
8-K
| Other Events Interactive Data |
08/07/2023 |
8-K
| Quarterly results |
07/12/2023 |
8-K
| Quarterly results |
07/07/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/12/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
05/08/2023 |
8-K
| Quarterly results |
04/06/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
03/06/2023 |
8-K
| Quarterly results |
01/06/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
11/07/2022 |
8-K
| Quarterly results |
09/29/2022 |
8-K
| Quarterly results |
08/08/2022 |
8-K
| Quarterly results |
06/17/2022 |
8-K
| Quarterly results |
06/08/2022 |
8-K
| Quarterly results |
05/09/2022 |
8-K
| Quarterly results |
02/28/2022 |
8-K
| Quarterly results |
02/07/2022 |
8-K
| Quarterly results |
11/08/2021 |
8-K
| Quarterly results |
09/22/2021 |
8-K
| Quarterly results |
08/09/2021 |
8-K
| Quarterly results |
08/09/2021 |
8-K
| Quarterly results |
07/22/2021 |
8-K
| Quarterly results |
06/22/2021 |
8-K
| Quarterly results |
06/04/2021 |
8-K
| Quarterly results |
05/05/2021 |
8-K
| Quarterly results |
04/29/2021 |
8-K
| Quarterly results |
04/27/2021 |
8-K
| Quarterly results |
03/11/2021 |
8-K
| Quarterly results |
02/12/2021 |
8-K
| Quarterly results |
01/20/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
01/08/2021 |
8-K
| Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits I... |
12/18/2020 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data
Docs:
|
"UNDERWRITING AGREEMENT",
"Letter re: Prospectus Supplement to Registration Statement on Form S-3",
"Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock",
"Ocular Therapeutix TM Announces Pricing of Public Offering of Common Stock BEDFORD, Mass, December 15, 2020 - Ocular Therapeutix™, Inc. , a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 3,725,000 shares of its common stock at a public offering price of $21.50 per share for gross proceeds of approximately $80.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters of the offering a 30-day option to purchase up to an additional 558,750 shares in the public offering on the same terms and conditions. Al..." |
|
|